Loading...
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
BACKGROUND: Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC). We carried out a randomized, open-label, phase III trial to determine whether S-1 and irinotecan plus bevacizumab is noninferior to m...
Na minha lista:
| Udgivet i: | Ann Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5889030/ https://ncbi.nlm.nih.gov/pubmed/29293874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx816 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|